Durata Therapeutics was a clinical development stage company in the

pharmaceutical industry The pharmaceutical industry discovers, develops, produces, and markets drugs or pharmaceutical drugs for use as medications to be administered to patients (or self-administered), with the aim to cure them, vaccinate them, or alleviate symptoms. ...

which focused on the treatment of

infection An infection is the invasion of tissues by pathogens, their multiplication, and the reaction of host tissues to the infectious agent and the toxins they produce. An infectious disease, also known as a transmissible disease or communicable dis ...

s. On November 17, 2014, the company was acquired by Actavis (now

Allergan Allergan plc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology. ...

) for $675 million.

History

On December 21, 2009, the company acquired Vicuron Pharmaceuticals and its drug candidate,

dalbavancin Dalbavancin, sold under the brand names Dalvance in the US and Xydalba in the EU among others, is a second-generation lipoglycopeptide antibiotic medication. It belongs to the same class as vancomycin, the most widely used and one of the treatm ...

, a long-acting semisynthetic

lipoglycopeptide Lipoglycopeptides are a class of antibiotic that have lipophilic side-chains linked to glycopeptides. The class includes oritavancin, telavancin and dalbavancin. In September 2009 the US Food and Drug Administration (FDA) approved telavancin (Vib ...

antibiotic, from

Pfizer Pfizer Inc. ( ) is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer ...

and commenced operations. On April 19, 2011, the company initiated Phase III studies of dalbavancin for intravenous (IV) treatment of acute bacterial skin and skin structure infections. In 2012, the company moved its global headquarters from Morristown to

Chicago (''City in a Garden''); I Will , image_map = , map_caption = Interactive Map of Chicago , coordinates = , coordinates_footnotes = , subdivision_type = Country , subdivision_name ...

and received $2 million in tax credits.

References

{{DEFAULTSORT:Durata Therapeutics Pharmaceutical companies disestablished in 2014 2009 establishments in New Jersey 2014 mergers and acquisitions American companies disestablished in 2014